These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 25750634)
1. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes. Greenbaum L; Lerer B Front Neurol; 2015; 6():27. PubMed ID: 25750634 [TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Cho CH; Lee HJ Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399 [TBL] [Abstract][Full Text] [Related]
4. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Greenbaum L; Smith RC; Lorberboym M; Alkelai A; Zozulinsky P; Lifschytz T; Kohn Y; Djaldetti R; Lerer B Psychopharmacology (Berl); 2012 Apr; 220(3):519-28. PubMed ID: 21947317 [TBL] [Abstract][Full Text] [Related]
5. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. Loonen AJ; Wilffert B; Ivanova SA Pharmacogenomics; 2019 Nov; 20(17):1199-1223. PubMed ID: 31686592 [TBL] [Abstract][Full Text] [Related]
6. An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice. Huh E; Choi JG; Sim Y; Oh MS Front Aging Neurosci; 2018; 10():431. PubMed ID: 30666195 [TBL] [Abstract][Full Text] [Related]
7. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3 Suarez LM; Alberquilla S; García-Montes JR; Moratalla R J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281 [TBL] [Abstract][Full Text] [Related]
8. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Seigneurie AS; Sauvanaud F; Limosin F Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134 [TBL] [Abstract][Full Text] [Related]
9. Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients. Vaiman EE; Shnayder NA; Novitsky MA; Dobrodeeva VS; Goncharova PS; Bochanova EN; Sapronova MR; Popova TE; Tappakhov AA; Nasyrova RF Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440083 [TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Ward KM; Citrome L Neurol Ther; 2018 Dec; 7(2):233-248. PubMed ID: 30027457 [TBL] [Abstract][Full Text] [Related]
11. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565 [TBL] [Abstract][Full Text] [Related]
12. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors. Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596 [TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632 [TBL] [Abstract][Full Text] [Related]
14. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII. Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071 [TBL] [Abstract][Full Text] [Related]
15. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
16. The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. Sano H; Nambu A Neurochem Int; 2019 Mar; 124():171-180. PubMed ID: 30639196 [TBL] [Abstract][Full Text] [Related]
17. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients. Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529 [TBL] [Abstract][Full Text] [Related]
18. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284 [TBL] [Abstract][Full Text] [Related]
19. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. Quik M; Bordia T; Zhang D; Perez XA Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532 [TBL] [Abstract][Full Text] [Related]